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Abstract
Valsartan, losartan, and irbesartan, are widely used in the treatment strategies of cardiovascular medi-
cine diseases, including hypertension and heart failure. Recently, many formulations for the aforemen-
tioned diseases contained active pharmaceutical ingredients and had been abruptly recalled from the 
market due to safety concerns mainly associated with unwanted impurities — nitrosamines, which are 
highly carcinogenic substances accidentally produced during manufacturing. Along with cardiovascular 
medications, formulations containing ranitidine were also recalled from the market. This poses a par-
ticular threat to public health due to the non-prescription status of these drugs. Regulatory authorities,  
including the Food and Drug Administration and European Medicines Agency among others, have 
taken action to minimize patient risk and improve the manufacturing quality as well as re-checking 
current guidelines and recommendations. While these steps are necessary to avoid further recalls, au-
thorities should remember the growing concerns of patients regarding the safety and efficacy of pharma-
cotherapy. Apart from the genuine manufacturing mistakes mentioned above, falsified and counterfeit 
medications should be at the heart of global attention. The lack of a well-accepted definition of falsified/ 
/counterfeit medications has impeded political and scientific efforts to mitigate risk of this phenomenon. 
Falsified Medicines Directive should be considered the most pivotal legislation recently enacted to har-
monize international cooperation. In summary, one should remember that only international and direct 
collaboration between patients, stakeholders, and authorities be considered a remedy for a pandemic of 
falsified medicines and plague of unexpected recalls due to safety concerns. (Cardiol J)
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Introduction: The complexities  
of pharmaceutical policy 
One of the primary purposes of pharmaceuti-
cal policy is to ensure that patients have access to 
effective and safe medicines, safe not only in terms 
of acceptable risk associated with the treatment but 
also regarding the quality of drug formulation [1]. 
International differences, complex characteristics 
of the pharmaceutical market with sometimes 
conflicting objectives among stakeholders, and 
the rapid development of pharmaceutical and 
medical sciences have multiplied problems with 
good governance of the pharmaceutical market, 
and have constituted a significant challenge for 
contemporary authorities [2]. Moreover, any rea-
sonable and well-planned pharmaceutical policy 
should minimize drug shortages — an issue that 
is increasingly difficult to cope with [3]. Drug re-
importation in countries with a well-developed 
pharmaceutical market can, however, decrease the 
risk of drug shortages, and should be planned as 
part of pharmaceutical strategy authorized by gov-
ernments responsible for public health [4, 5]. On 
the other hand, re-importation and parallel import, 
the latter known commonly in the European Union, 
can introduce drugs of unknown and substandard 
quality into the market, not to mention falsified and 
counterfeit medications [6]. 
Due to the fact that medications should have 
the highest possible quality, both governments and 
scientific bodies have created a set of legal and 
ethical guidelines aimed at ensuring patient safety 
[7, 8]. From the perspective of clinical importance, 
clinical drug effectiveness is tested extensively 
during clinical evaluations, mostly randomized 
controlled trials [9, 10]. When drugs are introduced 
into the market, post-authorization safety studies 
are conducted to detect adverse events, which can-
not be noticed in pre-marketing phases, and must 
be established in epidemiological studies, predomi-
nantly in the field of pharmacoepidemiology [11]. 
While much is known about clinical signifi-
cance, less attention has been paid to drug for-
mulation, at least from the healthcare providers’ 
perspective [12]. However, recent unintended 
drug recalls have forced us to reframe drug quality 
mostly as an international problem connecting all 
parties involved in drug production and distribu-
tion. Nagaich and Sadhna [13] listed several causes 
behind drug recalls, inter alia, label error in terms 
of declared dose, non-satisfactory stability, and, in 
recent cases, unwanted and potentially harmful 
substances. As a consequence, drug recalls due to 
safety issues may be one of the many causes re-
sponsible, at least temporarily, for drug shortages. 
Thus, it is no surprise that effective mecha-
nisms aimed at recalling a drug from the market, 
whenever necessary to ensure patient safety, 
must be implemented in harmony with a legal 
framework, and  routine practice. The community 
pharmacy is importantly placed in this process and 
implies a core role of pharmacists in the protection 
of public health and patient safety [14]. Greater 
access to new media and the internet can facili-
tate this role significantly, on the other hand, and 
it may lead to an unwanted dissemination of false 
information and create unnecessary fear among 
chronically ill patients [15].
This paper aims to outline the recent drug recall 
events and their consequences for patient safety 
and global health and provide a brief commentary 
on the phenomenon of falsified medicines. Both is-
sues are discussed, whenever possible, in the light 
of medications used in cardiovascular medicine, 
the treatment of hypertension, and heart failure. 
What should be stressed here is that the societal 
perspective remains at the core of deliberations 
and to emphasize public health implications from 
a plague of unexpected drug recalls and the pandemic 
of falsified medications, particularly with respect 
to medication adherence when it comes to trust in 
the medical profession and conventional medicine.
What are SSFFC? Drug recall  
versus drug withdrawal
Before talking about drug recalls based on 
safety issues, the acronym ‘SSFFC’ should be 
mentioned here (S — substandard, S — spurious, 
F — falsely labeled, F — falsified, C — counter-
feit), as suggested by the World Health Organiza-
tion (WHO) (Table 1). Although this classification 
seems to be useful, there is still no universally 
agreed definition of falsified/counterfeit drugs; 
thus, scientific deliberation and discussion are 
significantly impeded, which has also affected the 
international cooperation necessary to eliminate 
this phenomenon from the market. 
Similarly, the WHO approach is determined to 
distinguish medicinal products that are intentionally 
falsified from substandard products mainly introduced 
into the market as the result of an unintentional 
mistake [16]. In 2017, the WHO decided to push for 
greater transparency and simplification of terminol-
ogy. According to WHO, i) substandard medicinal 
products are those drugs manufactured ‘out of speci-
fication’; ii) unregistered/unlicensed products are 
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produced and distributed against national regulation, 
and iii) falsified products ‘intentionally’ misrepresent 
their identity, composition or source’ [17].
Additionally, drug recall should be recognized 
as a different concept from drug withdrawal, when 
drugs are removed from the market due to unwant-
ed drug events. Until new studies are provided, 
a particular medication which should no longer 
be used by patients. This procedure is illustrated by 
the cases of valdecoxib and rofecoxib, nonsteroidal 
anti-inflammatory drugs previously widely used in 
rheumatoid arthritis, withdrawn from the market due 
to increased cardiovascular risk among patients [18].
Falsified medications: A global challenge 
for the pharmaceutical policy
Although this paper aims not to describe falsi-
fied medications in great detail, some issues should 
be briefly highlighted with examples. As with 
recalled and withdrawn drugs, falsified medicines 
pose a challenge for pharmaceutical policy and 
international cooperation, and all actions aimed to 
mitigate the risk for patients are highly warranted 
[19]. One of the leading causes of this phenomenon 
has been the lack of international legislation; how-
ever, recently introduced Falsified Medicines Di-
rective (FMD) and acts enacted by Food and Drug 
Administration (FDA) has significantly improved 
the situation. One can hardly underestimate the 
role of the above-mentioned legal acts in the global 
fight against falsified and counterfeit medications. 
Corruption, the complexity of stakeholders in-
volved in drug distribution, high market prices, and 
many other factors have impacted globalization of 
the phenomenon. Considering this problem, there 
is also important financial and humanistic burden. 
On the one hand, this practice is associated with 
high income for parties involved in this crime. On 
the other hand, it may lead to a poorer prognosis, 
disability and, in some dramatic scenarios, death 
[20]. Finally, patient safety remains at significant 
risk whenever even a single falsified drug is made 
available on the market. Beyond reasonable doubt, 
it can be assumed that constant improvement 
in drug quality along with close and transparent 
cooperation between stakeholders can not only 
minimize the risk of the occurrence of unwanted 
falsified drugs in legal distribution but can also 
lead to better allocation of finite drug supplies [21]. 
It can be admitted here that there is a lit-
tle terminological discrepancy between falsified 
medications, which are deliberately falsified and 
introduced into the market as an imitation of non-
-falsified drugs, and those medications which are 
produced in violation of intellectual property rights. 
European legislation, particularly in the FMD, 
falsified medicines are accepted as the best way to 
describe deliberate misrepresentation. Borup et al. 
[22] have noticed that creating the legal framework 
in the pharmaceutical sector is a complex task 
requiring a multidimensional approach and harmo-
nization of national legislation with European legal 
acts, which was clearly seen in the FMD. At least 
in Europe, this act had started a broad discussion 
on the quality of drugs dispensed in legal distribu-
tion. According to the prior-mentioned study, legal 
purposes for instance; harmonization of definition 
were more established in the current European 
pharmaceutical policy than public health issues 
[22]. Moreover, the rigid approach authorized by 
the European Commission may not adequately 
respond to local needs [23, 24]. 
Falsified medications  
in cardiovascular medicine
Since cardiovascular diseases are highly preva-
lent in the population, cardiovascular medications 
are widely used, and due to the chronic nature of 
Table 1. Substandard and Falsified Medicinal Products according to World Health Organization (2011) 
— summary [54].
Term Definition
S — Substandard Medicines produced not in line with specifications, including intentional and  
negligent mistakes, not including genuine manufacturing errors
S — Spurious Products falsely labeled or intended to deceive; the term used mostly in South Asia
F — Falsely labelled Genuine products with false packaging
F — Falsified Products introduced into the market with deliberate intention to mimic original  
formulation and deceive stakeholders; definition widely used in European legal 
framework
C — Counterfeit Violation of intellectual property rights, mostly used in the United States
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cardiovascular diseases, in most cases, it is long- 
-term therapy, from the initial diagnosis to death [25, 
26]. In 2005, falsified atorvastatin was identified 
in the legal distribution in the United Kingdom 
[27]. Clopidogrel, an antiplatelet agent, was also 
falsified in the United Kingdom. It should be noted 
that falsified stocks were obtained via parallel 
distribution, and traceability was highly impeded 
in this case. It was eventually revealed that for-
mulation had not contained a sufficient amount of 
the active substance, which might have affected 
clinical efficacy [28, 29]. It is worth remember-
ing. One cannot forget the heparin adulteration, 
which occurred in the United States in 2008. As 
a consequence of this affair, 81 people were killed, 
and almost 800 patients were severely harmed. 
They have been living and will live with long-
-standing health problems for the rest of their lives 
[30]. Good Manufacturing Practice violations were 
also identified in the heparin-related case of 2016. 
However, it did not have direct severe repercus-
sions on patient health [31].
Substandard and falsified medications are 
a serious problem for developing countries. An-
tignac et al. [32] investigated the quality of car-
diovascular drugs in 10 Sub-Saharan Countries 
(The Seven Study), and revealed that almost 20% 
of analyzed formulations had been classified to 
be of poor quality. The authors did not decide to 
conduct a forensic investigation and trace whether 
a particular formulation was falsified or was sub-
standard, which should be considered a significant 
limitation. According to available research, this 
paper is a unique study; since there is a lack of 
research aimed at a particular class of drugs used 
in a specialized field of medicine, as was stated in 
the original paper. The fake amlodipine was also 
distributed in Kenya in 2014. Patients were offi-
cially informed about the potential risks related to 
the use of this falsified medication. Moreover, the 
differences between the original and fake packages 
were provided in official communications [33].
The plague of ‘unwanted’ drug recalls
Valsartan recall has been widely discussed in 
international media [34–36]. The formulations con-
taining valsartan were recalled due to identified con-
tamination with N-nitroso dimethylamine (NDMA), 
a potentially cancerogenic substance, resulting from 
unintended changes in the manufacturing process 
in China. Since contamination was related to an 
active pharmaceutical ingredient production, more 
than one brand had to be removed from the market. 
Moreover, due to the chronic nature of both 
arterial hypertension and congestive heart failure 
— two of the most common indications for its 
use — valsartan is often prescribed for long-term 
therapy, which could potentially cause prolonged 
exposure to a cancerogenic substance, leading to 
substantial risk for developing malignancy [37, 38]. 
So far, studies have highlighted minimal short-term 
risk. Nevertheless, the real consequences should 
be a matter for further scientific and clinical discus-
sion, also in terms of preventive screening among 
those exposed to the contamination over a long 
period [39, 40]. 
Cable News Network provided a list of recom-
mendations to minimize the dissemination of false 
information among patients who used valsartan-
containing products. The first piece of advice em-
phasized that some formulations, still available on 
the market at that moment, were safe for patients 
and did not contain hazardous contaminants. The 
media corporation also suggested that there were 
safe alternatives for patients, mostly in terms of 
drug equivalents, e.g., drugs belonging to a differ-
ent therapeutic group with a similar hypotensive 
effect and toxicity profile, which can be a reason-
able alternative for valsartan. The next part of the 
article described the association between exposure 
to contamination and cancer growth. Finally, the 
last piece of advice explained that using drugs 
should not be understood as a substitute for a good 
lifestyle, which is generally true, and applied not 
only to valsartan recall [41]. European Medicines 
Agency (EMA) urged national regulatory agencies 
to take appropriate steps to monitor drugs contain-
ing valsartan, specifically those produced in China. 
Nevertheless, in an official press release, EMA 
emphasized that all actions taken by authorities 
were precautionary, and actual risk to patients 
remained under control [42]. 
The contamination with NDMA is also a key 
reason behind the recall of formulations contain-
ing ranitidine. The FDA announced that, though 
unintended contamination was detected, the risk 
to patients was minimal since the level of NDMA 
barely exceeded concentration in food eaten on 
a daily basis by the vast majority of people around 
the world [43]. FDA, in a set of official public re-
leases, revealed various aspects of valsartan and ra-
nitidine recalls. FDA emphasized that an essential 
part of the recall was to educate patients about pos-
sible alternatives for ranitidine, and that patients 
should not stop their treatment unless they receive 
personalized recommendations from healthcare 
professionals [44]. It is important to note that 
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press releases were highly reassuring, brought the 
emotional level down, and emphasized the role of 
patient-oriented education as a tool for securing 
safety [45]. In addition, the FDA also revealed 
unwanted deviations from Good Manufacturing 
Practice, e.g., lack of adequate written procedures 
and problems with cleaning equipment used in drug 
production. Canadian authorities indicated that the 
problem with drugs containing ranitidine shared 
many similarities with a previously-described case 
with valsartan; however, since ranitidine is avail-
able over-the-counter, practical implications may 
have more serious consequences [46]. 
In light of all cases, the EMA recommended 
taking a proactive role and to extend the experience 
gained in valsartan and ranitidine-related cases to 
all medications. All actions should be aimed at reas-
suring patients that medicines are safe, effective, 
and without potentially cancerogenic ingredients, 
at least from a clinically relevant point of view. 
A different set of regulations should be given to 
clarify how to prevent future contamination with 
the NMDA [47]. 
The unwanted contamination of medicinal 
products containing valsartan and ranitidine had 
multiple repercussions in less developed coun-
tries as well. Safety alerts and drug recalls were 
introduced in Pakistan, where seven products 
with valsartan had been recalled from the market 
immediately after an official statement was author-
ized by American and European agencies had been 
published [48]. On the other hand, Moldova does 
not have well-prepared procedures regarding drug 
recalls, and the current situation there remains 
unclear [49]. 
Losartan and irbesartan were also investigated 
in terms of nitrosamine impurities [50]. As a result 
of this investigation, formulations containing lo-
sartan and losartan with hydrochlorothiazide were 
also recalled from the market; however, it should 
be noted that some products were recalled volun-
tarily by manufacturers just after the first signals 
from the market [51]. The same procedure was also 
implemented in the case of products containing 
irbesartan. In both above-mentioned cases, media 
attention was less prominent compared with the 
‘plague’ of valsartan recalls [52, 53].  
Summary
Falsified and substandard medications are 
an important threat to patient safety and public 
health. The occurrence of falsified medications in 
legal distribution has been making this situation 
even worse, particularly since over-the-counter 
medications are among the most frequently falsi-
fied categories of medications. The examples of 
falsified cardiovascular medications have con-
firmed that this phenomenon is, however, not only 
limited to non-prescription drugs. The second 
problem described in the paper herein, refers 
to drug recalls due to safety concerns. In recent 
years, many formulations used in cardiovascular 
medicine have been recalled from the market due 
to unwanted impurities or potentially carcinogenic 
substances. Both phenomena may have an impact 
on a patients’ perspective on the safety and effec-
tiveness of pharmacotherapy, potentially including 
hard outcomes. In this field, further studies are 
strongly recommended. Similar situations of a 
mass drug recall, as well as drug counterfeiting, 
should not take place. Authorities and parties 
involved in creating pharmaceutical policy should 
focus on ensuring patient safety, both from a legal 
and a societal point of view.
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